Controlled Clinical Trials

skingenix

The following controlled clinical trials were conducted to evaluate the efficacy of MEBO in the treatment of burns, chronic wounds, ulcers and scars.

List of Selected Publication Topics:

Controlled Clinical Trials in Burns

Moist Exposed Burn Ointment (MEBO) in Partial Thickness Burns

A New Approach to Local Burn Wound Care: Moist Exposed Therapy. A Multiphase, Multi-center Study

MEBO Ointment in the Treatment of Burn Wounds: A Multi-center Study

The Role of Alternative Therapy in the Management of Partial Thickness Burns of the Face - Experience with the Use of MEBO Compared with Silver Sulphadiazine

Evaluating the Role of Alternative Therapy in Burn Wound Management: Randomized Trial Comparing MEBO with Conventional Methods in the Management of Patients with Second-degree Burns

Benefit-Cost Analysis of Moist Exposed Burn Ointment

Cost-Effectiveness of Moist Exposed Burn Therapy

Clinical Trial Report of Burns Regenerative Medicine and Therapy – a Multi-center Phase III Study

Clinical Studies in Chronic Wounds, Ulcers and Scars

Efficacy of MEBO in the Management of Cutaneous Wounds and Ulcers: A Multi-center Pilot Study

Improving Scar Quality: A Prospective Clinical Study

Treatment of Toxic Epidermal Necrolysis with Moisture-Retentive Ointment: A Case Report and Review of the Literature

Clinical Use of MEBO in Wounds Management in U.A.E.

Observational Studies on Use of MEBO and Scar Ointment in a Clinic Setting

Successful Combined Treatment with Total Parenteral Nutrition Fluid

The Skingenix, Inc. website has been designed for the audience worldwide. This website contains information about products which may or may not be available in different countries. In addition, the official approval or market clearance for indications of use may also differ per each country. Please consult individual country sites for approved uses and any applicable restrictions.The research data disclosed in this website is wholly for the purpose of scientific information exchange and is not intended for marketing or promotional uses.

Please note that Skingenix's drug product MEBO® Wound Ointment has not been approved by the Food and Drug Administration for any indication of use in the United States. It is currently under the status of Investigational New Drug (Phase II) for patients with burn injuries, venous stasis ulcers and diabetic foot ulcers.